← Library
CJC-1295 (with DAC)
Research Use
Also known as CJC-1295 DAC, DAC-GHRH
Function
Primary
GH pulse amplification · IGF-1 elevation
Secondary
Body composition · Anti-aging
Mechanism
GHRH analog with C8 fatty-acid DAC modification — extends half-life to 6–8 days; stimulates pituitary GH release; raises IGF-1 chronically.
Evidence
Pre-clinical / Observational
Research
Phase I/II (Teichman 2006); no Phase III
Dosing
Range
1–2 mg/week
Frequency
Weekly or biweekly
Route
Subcutaneous
Cycling
8–12 weeks on / 4 weeks off.
Benefits
- ·Sustained GH/IGF-1 elevation
- ·Convenient weekly dosing
- ·Improved body composition (anecdotal)
Risks
- ·Loss of GH pulsatility
- ·Water retention
- ·Tingling/numbness
- ·Elevated IGF-1 oncogenicity concern
Contraindications
- ·Active malignancy
- ·Pregnancy
- ·Severe diabetic retinopathy
Regulatory
Not FDA-approved; compounded/research use
Functional Groups
Cited Works
- Teichman SL et al. Prolonged Stimulation of GH and IGF-I Secretion by CJC-1295. J Clin Endocrinol Metab. 2006;91:799.source